**SUBSECTION E.2: CSF/ICP DYNAMICS & MATHEMATICAL MODELING IN IIH and
SUBSECTION E.3: CSF PRODUCTION, CHOROID PLEXUS & GLYMPHATIC/CLEARANCE
PHYSIOLOGY**

STUDY_ID,FIRST_AUTHOR,YEAR,JOURNAL,ARTICLE_TYPE,MODEL_SCOPE,IIH_SPECIFIC,POPULATION_TYPE,DATA_SOURCE_TYPE,MODEL_ID,MODEL_NAME_AS_REPORTED,MODEL_TYPE,MODEL_DIMENSION,MODEL_COMPARTMENTS_TEXT,INCLUDES_VENOUS_SINUS_STENOSIS,INCLUDES_GLYMPHATIC,INCLUDES_COMPLIANCE,INCLUDES_VENOUS_PRESSURE,INCLUDES_RESPIRATORY_OR_CARDIAC_WAVES,PARAMETER_ID,PARAMETER_NAME,PARAMETER_SYMBOL,PARAMETER_CATEGORY,PARAMETER_DEFINITION_TEXT,PARAMETER_VALUE,PARAMETER_UNITS,PARAMETER_RANGE_TEXT,PARAMETER_CONTEXT_TEXT,PARAMETER_SOURCE_LOCATION,PRIMARY_OUTCOMES_MODELLED_TEXT,NOTES_FOR_IMPLEMENTATION,PDF_SOURCE_IDENTIFIER

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH;SymptomaticControls,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P01,Mean CSF
pressure,Mean CSF pressure,Pressure,\"Mean CSF pressure from lumbar
measurement\",20.7,mmHg,7.75 (IQR),Verified IIH cases (N=39),Table
3,Comparison of ICP parameters in IIH vs Controls,Uses CELDA system;
lumbar pressure used as proxy for ICP.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,SymptomaticControls,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P02,Mean CSF
pressure,Mean CSF pressure,Pressure,\"Mean CSF pressure from lumbar
measurement\",13.0,mmHg,6.5 (IQR),Symptomatic controls (N=20),Table
3,Comparison of ICP parameters in IIH vs Controls,Uses CELDA system;
lumbar pressure used as proxy for ICP.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P03,Pulse
amplitude,AMP,Pressure,\"Mean pulse amplitude
(cardiac-related)\",4.5,mmHg,6.0 (IQR),Verified IIH cases (N=39),Table
3,Comparison of ICP parameters in IIH vs Controls,Cardiac-related wave
amplitude.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,SymptomaticControls,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P04,Pulse
amplitude,AMP,Pressure,\"Mean pulse amplitude
(cardiac-related)\",1.5,mmHg,2.6 (IQR),Symptomatic controls (N=20),Table
3,Comparison of ICP parameters in IIH vs Controls,Cardiac-related wave
amplitude.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P05,Respiratory
waves power,RESP,Pressure,Power of respiratory waves,0.8,mmHg,0.5
(IQR),Verified IIH cases (N=39),Table 3,Comparison of ICP parameters in
IIH vs Controls,Reflects venous pressure
variations.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P06,Slow waves
power,SLOW,Pressure,\"Power of slow waves (B-waves, 0.0055-0.05
Hz)\",1.0,mmHg,1.1 (IQR),Verified IIH cases (N=39),Table 3,Comparison of
ICP parameters in IIH vs Controls,Reflects slow ICP
variations.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P07,RAP
index,RAP,Compliance,\"Correlation between AMP and ICP (compliance
state)\",0.82,unitless,0.29 (IQR),Verified IIH cases (N=39),Table
3,Comparison of ICP parameters in IIH vs Controls,High value = low
compliance.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,SymptomaticControls,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P08,RAP
index,RAP,Compliance,\"Correlation between AMP and ICP (compliance
state)\",0.63,unitless,0.58 (IQR),Symptomatic controls (N=20),Table
3,Comparison of ICP parameters in IIH vs Controls,High value = low
compliance.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P09,Relative
pulse pressure coefficient,RPPC,Compliance,\"Slope of AMP vs ICP
(pressure independent compliance)\",0.52,unitless,0.26 (IQR),Verified
IIH cases (N=30),Table 3,Comparison of ICP parameters in IIH vs
Controls,Reflects steepness of P/V curve.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,ClinicalICPData,M01,CELDA
analysis,Statistical,NotSpecified,NR,No,No,Yes,Yes,Yes,P10,Pressure
constant,P0,Pressure,\"Intercept of AMP vs ICP regression (venous
pressure proxy)\",10.8,mmHg,4.4 (IQR),Verified IIH cases (N=30),Table
3,Comparison of ICP parameters in IIH vs Controls,\"Baseline pressure
constant, suggested to depend on venous
pressure\",s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,LiteratureParameters,M02,Literature
Review Summary,Qualitative,NotSpecified,NR,Yes,No,Yes,Yes,No,P01,CSF
outflow resistance,R,CSF_OutflowResistance,Resistance to CSF
outflow,Increased,NR,NR,IIH patients (literature review),Table 1; p.
3361,Summary of 19 studies.,Supports Rcsf as a key parameter for IIH
models.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,LiteratureParameters,M02,Literature
Review
Summary,Qualitative,NotSpecified,NR,Yes,No,Yes,Yes,No,P02,Sagittal sinus
pressure,SSP,Pressure,Sagittal sinus pressure,Elevated,NR,NR,IIH
patients (literature review),Table 1; p. 3361,Summary of 19
studies.,Supports Pvs as a key parameter for IIH
models.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,LiteratureParameters,M02,Literature
Review
Summary,Qualitative,NotSpecified,NR,Yes,No,Yes,Yes,Yes,P03,Craniospinal
elastance,E,Elasticity,Craniospinal elastance (inverse of
compliance),Higher,NR,NR,IIH patients (literature review),Table 1; p.
3361,Summary of 19 studies.,Supports elastance/compliance as key
parameter.,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,LiteratureParameters,M02,Literature
Review
Summary,Qualitative,NotSpecified,NR,Yes,No,Yes,Yes,Yes,P04,Pressure
volume index,PVI,Compliance,Pressure volume index,Decreased,NR,NR,IIH
patients (literature review),Table 1; p. 3361,Summary of 19
studies.,Supports compliance as key parameter (PVI related to
C).,s00701-021-04940-x.pdf

Kaipainen_2021_ActaNeurochir,Kaipainen,2021,Acta Neurochir
(Wien),ReviewWithModel,IIH_CSFDynamics,Yes,IIH,LiteratureParameters,M02,Literature
Review
Summary,Qualitative,NotSpecified,NR,Yes,No,Yes,Yes,Yes,P05,B-waves,B-waves,Pressure,\"Slow
waves (Lundberg B-waves)\",Present \>50% of time,NR,NR,IIH patients
(Gjerris et al. 1985),Table 1; p. 3361,Summary of 19 studies.,Confirms
presence of slow waves in IIH.,s00701-021-04940-x.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P01,Arterial elastance
coefficient,Ka,Elasticity,Stressed elastance parameter
(arterial),0.58,ml\^-1,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P02,Arterial elastance
coefficient,Pa0,Elasticity,Unstressed elastance parameter
(arterial),3.82,mmHg,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P03,Venous elastance
coefficient,Kv,Elasticity,Stressed elastance parameter
(venous),1.87,ml\^-1,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P04,Venous elastance
coefficient,Pv0,Elasticity,Unstressed elastance parameter
(venous),3.78,mmHg,NR,Patient 1 (Normal ICP),Table 1,Models ICP waveform
morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P05,Intracranial elastance
coefficient,Kc,Elasticity,Stressed elastance parameter
(intracranial),2.23,ml\^-1,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P06,Intracranial elastance
coefficient,Pc0,Elasticity,Unstressed elastance parameter
(intracranial),10.30,mmHg,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P07,Spinal elastance
coefficient,Ks,Elasticity,Stressed elastance parameter
(spinal),1.50,ml\^-1,NR,Patient 1 (Normal ICP),Table 1,Models ICP
waveform morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P08,Spinal elastance
coefficient,Ps0,Elasticity,Unstressed elastance parameter
(spinal),5.55,mmHg,NR,Patient 1 (Normal ICP),Table 1,Models ICP waveform
morphology,Mono-exponential pressure-volume
relation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P09,CSF inertance,Ls,Other,\"Inertance of CSF
flow (intracranial to spine)\",0.04,mmHg s\^2/ml,NR,Patient 1 (Normal
ICP),Table 1,Models ICP waveform morphology,Based on unsteady Bernoulli
equation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P10,Venous exit inertance,Le,Other,\"Inertance
of venous outflow (exit)\",0.04,mmHg s\^2/ml,NR,Patient 1 (Normal
ICP),Table 1,Models ICP waveform morphology,Based on unsteady Bernoulli
equation.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P11,CSF
resistance,Bs,CSF_OutflowResistance,\"Bernoulli/resistance parameter
(CSF flow)\",0.16,mmHg s\^2/ml\^2,NR,Patient 1 (Normal ICP),Table
1,Models ICP waveform morphology,Resistance term is R =
B\*\|Q\|.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P12,Arteriovenous
resistance,Bv,Other,\"Bernoulli/resistance parameter (arteriovenous
flow)\",0.0025,mmHg s\^2/ml\^2,NR,Patient 1 (Normal ICP),Table 1,Models
ICP waveform morphology,Resistance term is R =
B\*\|Q\|.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P13,Venous exit
resistance,Be,Venous_Sinus_Resistance,\"Bernoulli/resistance parameter
(venous outflow)\",0.06,mmHg s\^2/ml\^2,NR,Patient 1 (Normal ICP),Table
1,Models ICP waveform morphology,Resistance term is R =
B\*\|Q\|.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P14,Intracranial elastance coefficient
(mean),Kc,Elasticity,Stressed elastance parameter
(intracranial),2.43,ml\^-1,0.63 (SD),All patients (N=10),Table 1,Models
ICP waveform morphology,Mean value across all 10
patients.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P15,Intracranial elastance (sensitivity),Kc or
Pc0,Elasticity,Parameters most notably affecting frequency of ICP
oscillations,NR,NR,NR,Sensitivity analysis,p. 3317 (text),Models ICP
waveform morphology,Frequency of oscillations directly proportional to
Kc or Pc0.,1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P16,Arterial elastance (sensitivity),Ka or
Pa0,Elasticity,Parameters affecting order of ICP peaks
(P1/P2/P3),NR,NR,NR,Sensitivity analysis,p. 3317 (text),Models ICP
waveform morphology,\"Large \*decrease\* in Ka or Pa0 influenced order
of peaks.\",1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P17,Venous elastance (sensitivity),Kv or
Pv0,Elasticity,Parameters affecting order of ICP peaks
(P1/P2/P3),NR,NR,NR,Sensitivity analysis,p. 3317 (text),\"Large
\*increase\* in Kv or Pv0 influenced order of
peaks.\",1-s2.0-S0022519323000474-main.pdf

Domogo_2023_JTheorBiol,Domogo,2023,J Theor
Biol,TheoreticalModel,SingleHeartBeat_ICP,No,IIH;Healthy,ClinicalICPData,M01,Mechanistic-mathematical
model,ODE;Compartmental,0D,arterial;venous;intracranial;spine;brain
tissue,No,No,Yes,Yes,Yes,P18,CSF resistance
(sensitivity),Bs,CSF_OutflowResistance,Parameters affecting order of ICP
peaks (P1/P2/P3),NR,NR,NR,Sensitivity analysis,p. 3317 (text),Models ICP
waveform morphology,\"\*Decrease\* in Bs influenced order of
peaks.\",1-s2.0-S0022519323000474-main.pdf

Eide_2021_BrainCommun,Eide,2021,Brain
Commun,ImagingStudy,IIH_Glymphatics,Yes,IIH;Healthy;OtherCNS,ImagingTracer,M01,Glymphatic
clearance
model,Qualitative,NotSpecified,Glymphatic;PerivascularSpace,No,Yes,No,No,No,P01,Glymphatic
clearance,NR,Flow,Tracer clearance from subarachnoid space (intrathecal
gadobutrol),Reduced,NR,NR,IIH (N=11) vs Controls (N=7),text p. 1,
6,Impaired glymphatic function in IIH,Model is conceptual/statistical,
not mechanistic ODE.,fcab043.pdf

Eide_2021_BrainCommun,Eide,2021,Brain
Commun,ImagingStudy,IIH_Glymphatics,Yes,IIH,ImagingTracer,M01,Glymphatic
clearance
model,Qualitative,NotSpecified,Glymphatic;PerivascularSpace,No,Yes,No,No,No,P02,Tracer
enrichment in PVS,NR,Other,\"Tracer enrichment in perivascular spaces
(PVS)\",Higher,NR,NR,\"IIH (N=11) vs Controls (N=7)\",text p. 6,Impaired
glymphatic function in IIH,Suggests impaired clearance \*from\* PVS, not
impaired influx.,fcab043.pdf

Eide_2021_BrainCommun,Eide,2021,Brain
Commun,ImagingStudy,IIH_Glymphatics,Yes,IIH,ImagingTracer,M01,Glymphatic
clearance
model,Qualitative,NotSpecified,Glymphatic;PerivascularSpace,No,Yes,No,No,No,P03,Tracer
clearance rate,NR,Rate,\"Tracer clearance rate from
parenchyma\",Reduced,NR,NR,\"IIH (N=11) vs Controls (N=7)\",text p.
6,Impaired glymphatic function in IIH,Suggests reduced ISF-to-CSF/venous
clearance.,fcab043.pdf

Eide_2021_BrainCommun,Eide,2021,Brain
Commun,ImagingStudy,IIH_Glymphatics,Yes,IIH,ImagingTracer,M01,Glymphatic
clearance
model,Qualitative,NotSpecified,Glymphatic;PerivascularSpace,No,Yes,No,No,No,P04,Tracer
time to peak (parenchyma),Tmax,TimeConstant,Time to maximum tracer
enrichment in parenchyma,Longer,NR,NR,\"IIH (N=11) vs Controls
(N=7)\",text p. 6,Impaired glymphatic function in IIH,Indicates slower
glymphatic clearance dynamics.,fcab043.pdf

Lenck_2018_Neurology,Lenck,2018,Neurology,ImagingStudy,IIH_Glymphatics;Venous,Yes,IIH;Healthy,ImagingTracer,M01,Veno-glymphatic
connections,Qualitative,NotSpecified,Glymphatic;VenousSinus,Yes,Yes,No,Yes,No,P01,Glymphatic
efflux,NR,Flow,\"Tracer (gadobutrol) clearance from CSF\",NR,NR,NR,IIH
(N=10) vs Healthy (N=5),Abstract; Fig 2,Tracer efflux correlates with
venous parameters.,Model is conceptual, based on imaging.,lenck2018.pdf

Lenck_2018_Neurology,Lenck,2018,Neurology,ImagingStudy,IIH_Glymphatics;Venous,Yes,IIH,ImagingTracer,M01,Veno-glymphatic
connections,Qualitative,NotSpecified,Glymphatic;VenousSinus,Yes,Yes,No,Yes,No,P02,Glymphatic
efflux pathway,NR,AnatomicalPathway,\"Tracer accumulation in venous
sinuses (SSS, sigmoid)\",Observed,NR,NR,IIH (N=10) and Healthy (N=5),Fig
2; text p. 518,Shows tracer efflux into venous sinuses, supporting
glymphatic-venous link.,lenck2018.pdf

Lenck_2018_Neurology,Lenck,2018,Neurology,ImagingStudy,IIH_Glymphatics;Venous,Yes,IIH,ImagingTracer,M01,Veno-glymphatic
connections,Qualitative,NotSpecified,Glymphatic;VenousSinus,Yes,Yes,No,Yes,No,P03,Glymphatic-venous
correlation,r,Correlation,\"Correlation (r) between glymphatic efflux
(SSS tracer) and Pgrad (VSS pressure gradient)\",0.86,NR,NR,IIH
(N=10),text p. 520,\"Strong positive correlation (p=0.001)\",Links
glymphatic clearance to VSS hemodynamics.,lenck2018.pdf

Lenck_2018_Neurology,Lenck,2018,Neurology,ImagingStudy,IIH_Glymphatics;Venous,Yes,IIH,ImagingTracer,M01,Veno-glymphatic
connections,Qualitative,NotSpecified,Glymphatic;VenousSinus,Yes,Yes,No,Yes,No,P04,Glymphatic-venous
correlation,r,Correlation,\"Correlation (r) between glymphatic efflux
(SSS tracer) and VSS % stenosis\",0.75,NR,NR,IIH (N=10),text p.
520,\"Strong positive correlation (p=0.01)\",Links glymphatic clearance
to VSS anatomy.,lenck2018.pdf

Lenck_2018_Neurology,Lenck,2018,Neurology,ImagingStudy,IIH_Glymphatics;Venous,Yes,IIH,ImagingTracer,M01,Veno-glymphatic
connections,Qualitative,NotSpecified,Glymphatic;VenousSinus,Yes,Yes,No,Yes,No,P05,Glymphatic-venous
hypothesis,NR,Mechanism,\"Hypothesis: VSS increases venous/glymphatic
resistance, impairing clearance, raising ICP.\",NR,NR,NR,IIH,text p.
521,Glymphatic impairment is part of VSS pathophysiology.,Links VSS
resistance to glymphatic resistance.,lenck2018.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,IIH;Controls,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P01,VSS
Prevalence (IIH),Prevalence,Proportion,Bilateral VSS prevalence in IIH
patients,93,%,NR,IIH (N=59),Table 1,Quantifies VSS prevalence in
IIH.,ajnr.A8088.full.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,Controls,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P02,VSS
Prevalence (Control),Prevalence,Proportion,Bilateral VSS prevalence in
control patients,7,%,NR,Controls (N=29),Table 1,Quantifies VSS
prevalence in Controls.,ajnr.A8088.full.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,IIH,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P03,VSS
Severity (IIH),Stenosis grade,Ordinal,\"Grade 3 or 4 (severe)
stenosis\",87,%,NR,IIH (N=59),text p. 1548,Quantifies severity of VSS in
IIH.,ajnr.A8088.full.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,IIH,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P04,VSS Mean
Stenosis (IIH),Stenosis,Proportion,\"Mean % stenosis (cross-sectional
area reduction)\",68,%,18 (SD),IIH (N=59),text p. 1548,Parameter for VSS
resistance calculation.,ajnr.A8088.full.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,Controls,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P05,VSS Mean
Stenosis (Control),Stenosis,Proportion,\"Mean % stenosis
(cross-sectional area reduction)\",22,%,16 (SD),Controls (N=29),text p.
1548,Parameter for VSS resistance calculation.,ajnr.A8088.full.pdf

Farb_2003_AJNR,Farb,2003,AJNR,ImagingStudy,VenousSinusHemodynamics,Yes,IIH,ImagingVenous,M01,VSS
prevalence
study,Statistical,NotSpecified,VenousSinus,Yes,No,No,Yes,No,P06,VSS
Morphology,Stenosis type,Categorical,\"Stenosis morphology:
tapered/smooth\",52,%,NR,IIH (N=55 with VSS),text p.
1549,Tapered/extrinsic (52%) vs abrupt/intrinsic
(48%).,ajnr.A8088.full.pdf

Code snippet

STUDY_ID,FIRST_AUTHOR,YEAR,JOURNAL,ARTICLE_TYPE,PREPARATION_TYPE,SPECIES,POPULATION_TYPE,N_SUBJECTS_OR_PREPARATIONS,STATEMENT_ID,ROW_TYPE,DOMAIN,VARIABLE_NAME_AS_REPORTED,VARIABLE_CATEGORY,MEASUREMENT_OR_CONCEPT_TEXT,DATA_TYPE,GROUP1_LABEL,GROUP1_MEAN,GROUP1_SD,GROUP1_N,GROUP2_LABEL,GROUP2_MEAN,GROUP2_SD,GROUP2_N,EFFECT_MEASURE_TYPE,EFFECT_VALUE,EFFECT_CI_LOWER,EFFECT_CI_UPPER,EFFECT_P_VALUE,DIRECTION_SUMMARY_TEXT,RELEVANCE_FOR_CSF_MODEL_TEXT,PDF_SOURCE_IDENTIFIER

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Human,Healthy,NR,S01,ReviewNumericSummary,CSF_Production,CSF
drainage rate (Human),Rate,\"Typical CSF drainage
rate\",\~500,ml/day,NR,NR,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF turns over
3-4 times a day.\",Sets baseline CSF production/drainage
rate.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,CSF_Production,Choroid
plexus (CP) as primary source,Mechanism,\"Traditional view: CP accounts
for majority of CSF
production.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CP is
the dominant source.\",Defines CP as main production
site.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,ChoroidPlexus_Transport,Ion
transporter polarization,Mechanism,\"Polarized distribution of ion
transporters (apical vs basolateral) drives CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Ion
transport polarity is key to secretion.\",Links transporters to
secretion mechanism.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Mouse,Healthy,NR,S04,ReviewNumericSummary,AQP1,AQP1
null mice CSF secretion,FractionContribution,\"AQP1 null mice have a 25%
reduction in CSF
secretion.\",Continuous,WT,NR,NR,NR,AQP1_KO,NR,NR,NR,PercentChange,-25,NR,NR,NR,NR,\"AQP1
genetic deletion reduces CSF secretion by 25%.\",Quantifies AQP1
contribution.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Mouse;
Dog,Healthy,NR,S05,ReviewNumericSummary,NKCC1,NKCC1 inhibition
(bumetanide, icv),FractionContribution,\"icv bumetanide (NKCC1
inhibitor) found a \~50% reduction in CSF secretion rate in
mice.\",Continuous,Control,NR,NR,NR,Bumetanide_icv,NR,NR,NR,PercentChange,-50,NR,NR,NR,NR,\"NKCC1
inhibition (icv) reduces CSF secretion by \~50%.\",Quantifies NKCC1
contribution.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Human,Healthy,NR,S06,ReviewNumericSummary,CSF_Production,Circadian
rhythm of CSF secretion,Rate,\"Human CSF secretion rate: max 42 mL/h
(02:00h), nadir 12 mL/h (18:00h).\",Continuous,Max (02:00h),42,NR,NR,Min
(18:00h),12,NR,NR,Ratio,3.5,NR,NR,NR,NR,\"CSF secretion has a strong
circadian rhythm (3.5-fold change).\",Defines time-varying nature of
production.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Rat,Healthy,NR,S07,ReviewNumericSummary,CSF_Production,Age-related
decline in CSF secretion,Rate,\"\~46% decline in CSF secretion between 3
and 30 months of age in
rat.\",Continuous,3_months,NR,NR,NR,30_months,NR,NR,NR,PercentChange,-46,NR,NR,NR,NR,\"CSF
secretion declines with age in rats.\",Defines age as a covariate for
production.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Rat,DiseaseModel,NR,S08,ReviewDirectional,NKCC1,NKCC1
phosphorylation in IVH,Mechanism,\"IVH stimulates bumetanide-inhibitable
CSF secretion via NKCC1 phosphorylation (SPAK
pathway).\",Conceptual,Control,NA,NA,NA,IVH,NA,NA,NA,NA,NA,NA,NA,NR,\"Inflammation
(IVH) increases NKCC1 activity.\",Links inflammation/SPAK to NKCC1
function.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Mouse,DiseaseModel,NR,S09,ReviewDirectional,NKCC1,NKCC1
reversal (Hydrocephalus),Mechanism,\"NKCC1 overexpression reduced
ventriculomegaly in neonatal hydrocephalus
models.\",Conceptual,WT,NA,NA,NA,NKCC1_OE,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1
may run \'inward\' (clearance) if CSF K+ is high.\",Highlights
bidirectional nature of NKCC1.,1-s2.0-S0969996123001730-main.pdf

Xiang_2023_NeurobiolDis,Xiang,2023,Neurobiol
Dis,NarrativeReview,NotSpecified,Rat,DiseaseModel,NR,S10,ReviewDirectional,TRPV4,TRPV4
antagonism in hydrocephalus,Mechanism,\"TRPV4 antagonists could reduce
ventriculomegaly in a rat model of
hydrocephalus.\",Conceptual,Control,NA,NA,NA,TRPV4_antagonist,NA,NA,NA,NA,NA,NA,NA,NR,\"TRPV4
channel involved in regulating CSF secretion.\",Identifies TRPV4 as a
potential target.,1-s2.0-S0969996123001730-main.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,CSF_Production,CSF
secretion vs osmotic gradient,Mechanism,\"Choroid plexus secretes fluid
in absence of, and even against, a transepithelial osmotic
gradient.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF
secretion is not driven by bulk osmosis.\",Refutes simple osmotic
models.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,ChoroidPlexus_Transport,Standing
gradient hypothesis,Mechanism,\"Standing gradient hypothesis (osmolyte
accumulation in lateral spaces) lacks experimental
support.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Refutes
classical standing gradient model.\",Refutes classical standing gradient
models.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,ChoroidPlexus_Transport,Transporter-mediated
water transport,Mechanism,\"Proposed mechanism: local hyperosmolar
compartment resides within the membrane transport proteins
themselves.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Hypothesizes
water co-transport with ions.\",Alternative model for non-osmotic water
flux.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,NKCC1,NKCC1
water transport,Mechanism,\"NKCC1 co-transports water with ions,
independent of osmotic
gradient.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1 is
a molecular water pump.\",Identifies NKCC1 as a water
co-transporter.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Mouse; Rat;
Dog,Healthy,NR,S05,ReviewNumericSummary,NKCC1,NKCC1 contribution to CSF
secretion,FractionContribution,\"NKCC1 contributes \~50% of total CSF
secretion (in mice, rats,
dogs).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,PercentContribution,50,NA,NA,NR,NR,\"NKCC1
activity is responsible for \~50% of CSF production.\",Quantifies NKCC1
contribution.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,NaK_ATPase,NaK-ATPase
inhibition (Ouabain),Mechanism,\"Ouabain (Na+/K+-ATPase inhibitor)
efficiently reduces CSF secretion when applied luminally
(i.c.v.).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA
inhibition reduces CSF secretion.\",Confirms NKA as primary
driver.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S07,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide (CA inhibitor) limits formation of
HCO3- required to drive choroidal HCO3-
transporters.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ
limits substrate (HCO3-) for secretion.\",Defines ACZ mechanism on ion
transport.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Mouse,Healthy,NR,S08,ReviewNumericSummary,AQP1,AQP1
contribution to CSF secretion,FractionContribution,\"CSF secretion is
only reduced 20% in mice genetically deficient of
AQP1.\",Continuous,WT,NR,NR,NR,AQP1_KO,NR,NR,NR,PercentChange,-20,NR,NR,NR,NR,\"AQP1
deletion has modest (20%) effect on CSF secretion.\",Quantifies AQP1
contribution.,12987_2022_Article_323.pdf

MacAulay_2022_FluidsBarriersCNS,MacAulay,2022,Fluids Barriers
CNS,ConceptualReview,NotSpecified,Rat,Healthy,NR,S09,ReviewNumericSummary,CSF_Drainage,CSF
drainage pathways (Rat),FractionContribution,\"CSF reabsorption in
rodents occurs mainly along cranial nerve sheaths (olfactory,
optic).\",Conceptual,CranialNerves,NR,NR,NR,AG,NR,NR,NR,NA,NA,NA,NA,NR,\"AGs
absent in rodents; drainage via lymphatics.\",Defines non-AG drainage
pathway in rodents.,12987_2022_Article_323.pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Human,Healthy,NR,S01,ReviewNumericSummary,CSF_Production,CSF
production rate (Human),Rate,\"Adult human CSF production rate is \~0.4
mL/min.\",Continuous,Human,0.4,NR,NR,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF
production rate is \~0.4 mL/min.\",Sets baseline CSF production
rate.,Clinical Anatomy - 2024 - Johnsen - Mechanisms of cerebrospinal
fluid secretion by the choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,CSF_Production,Choroid
plexus vs extrachoroidal,FractionContribution,\"Choroid plexus (CP)
epithelium secretes 50-80% of total
CSF.\",Conceptual,CP,NR,NR,NR,Extrachoroidal,NR,NR,NR,PercentContribution,50-80,NR,NR,NR,NR,\"CP
accounts for 50-80% of CSF production.\",Quantifies CP
contribution.,Clinical Anatomy - 2024 - Johnsen - Mechanisms of
cerebrospinal fluid secretion by the choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,ChoroidPlexus_Transport,NaK-ATPase
localization,AnatomicalPathway,\"Na+/K+-ATPase is primarily located on
the apical (CSF-facing) membrane of
CP.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is apical
(CSF-facing).\",Defines polarity of primary secretion driver.,Clinical
Anatomy - 2024 - Johnsen - Mechanisms of cerebrospinal fluid secretion
by the choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,NaK_ATPase,NaK-ATPase
role,Mechanism,\"Na+/K+-ATPase is the primary driving force for CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
the primary driver.\",Confirms NKA as primary driver.,Clinical Anatomy -
2024 - Johnsen - Mechanisms of cerebrospinal fluid secretion by the
choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S05,ReviewDirectional,NKCC1,NKCC1
localization,AnatomicalPathway,\"NKCC1 is located on the apical
(CSF-facing)
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1 is
apical (CSF-facing).\",Defines polarity of NKCC1.,Clinical Anatomy -
2024 - Johnsen - Mechanisms of cerebrospinal fluid secretion by the
choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,ChoroidPlexus_Transport,Basolateral
HCO3- transport,Mechanism,\"Basolateral transport (blood-side) relies on
HCO3- transporters (e.g., NCBE,
AE2).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Basolateral
HCO3- transporters are key.\",Defines basolateral ion loading
mechanism.,Clinical Anatomy - 2024 - Johnsen - Mechanisms of
cerebrospinal fluid secretion by the choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S07,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide inhibits carbonic anhydrase,
reducing H+ and HCO3- supply for transporters (NHE,
AE2).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ limits
substrates (H+, HCO3-) for transporters.\",Defines ACZ
mechanism.,Clinical Anatomy - 2024 - Johnsen - Mechanisms of
cerebrospinal fluid secretion by the choroid plexus epithelium .pdf

Johnsen_2024_ClinAnat,Johnsen,2024,Clin
Anat,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S08,ReviewDirectional,CSF_Production,CSF
secretion vs osmotic gradient,Mechanism,\"CSF secretion occurs against
an osmotic gradient (uphill water
transport).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF
secretion is non-osmotic.\",Refutes simple osmotic models.,Clinical
Anatomy - 2024 - Johnsen - Mechanisms of cerebrospinal fluid secretion
by the choroid plexus epithelium .pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,ChoroidPlexus_Transport,NaK-ATPase
localization,AnatomicalPathway,\"Na+/K+-ATPase is polarized to the
apical (CSF-facing)
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
apical (CSF-facing).\",Defines polarity of primary secretion
driver.,benarroch2016.pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,NKCC1,NKCC1
role,Mechanism,\"NKCC1 (apical) contributes to ion secretion into
CSF.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1 is an
apical secretor.\",Confirms apical NKCC1 role.,benarroch2016.pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,ChoroidPlexus_Transport,Basolateral
HCO3- transport,Mechanism,\"Basolateral Na+-HCO3- cotransport (NCBE) and
Cl-/HCO3- exchange (AE2) move ions from blood to CP
cell.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Basolateral
HCO3- transporters (NCBE, AE2) involved in ion loading.\",Defines
basolateral ion loading mechanism.,benarroch2016.pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide inhibits carbonic anhydrase (CA),
reducing CSF secretion by limiting H+ and HCO3- for
transport.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ
inhibits CA, reducing H+/HCO3- supply.\",Defines ACZ
mechanism.,benarroch2016.pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S05,ReviewDirectional,AQP1,AQP1
localization,AnatomicalPathway,\"AQP1 is highly expressed at the apical
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"AQP1 is
apical.\",Defines AQP1 polarity.,benarroch2016.pdf

Benarroch_2016_Neurology,Benarroch,2016,Neurology,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,Glymphatic,Glymphatic
system,Mechanism,\"Glymphatic system: CSF-ISF exchange via perivascular
spaces,
AQP4-dependent.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Glymphatic
pathway relies on AQP4.\",Defines glymphatic
mechanism.,benarroch2016.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewNumericSummary,CSF_Production,CSF
production rate (Human),Rate,\"Adult human CSF production rate \~0.3-0.4
ml/min.\",Continuous,Human,0.35,Range,0.3-0.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Human
CSF production rate \~0.3-0.4 ml/min.\",Sets baseline CSF production
rate.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,CSF_Production,Choroid
plexus vs extrachoroidal,FractionContribution,\"CP is responsible for
50-80% of total CSF
secretion.\",Conceptual,CP,NR,NR,NR,Extrachoroidal,NR,NR,NR,PercentContribution,50-80,NR,NR,NR,NR,\"CP
accounts for 50-80% of CSF production.\",Quantifies CP
contribution.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,ChoroidPlexus_Transport,NaK-ATPase
localization,AnatomicalPathway,\"Na+/K+-ATPase is strongly expressed at
the apical (CSF-facing)
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
apical (CSF-facing).\",Defines polarity of primary secretion
driver.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,NaK_ATPase,NaK-ATPase
inhibition (Ouabain),Mechanism,\"Apical (i.c.v.) ouabain inhibits CSF
secretion by
50-80%.\",Conceptual,Control,NR,NR,NR,Ouabain_icv,NR,NR,NR,PercentChange,-50-80,NR,NR,NR,NR,\"Apical
NKA inhibition strongly reduces CSF secretion.\",Quantifies NKA
contribution.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S05,ReviewDirectional,NKCC1,NKCC1
localization,AnatomicalPathway,\"NKCC1 (Slc12a2) is robustly expressed
at the apical
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1 is
apical.\",Defines NKCC1
polarity.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,NKCC1,NKCC1
inhibition (Bumetanide),Mechanism,\"Apical (i.c.v.) bumetanide inhibits
CSF
secretion.\",Conceptual,Control,NR,NR,NR,Bumetanide_icv,NR,NR,NR,NA,NA,NA,NA,NR,\"Apical
NKCC1 inhibition reduces CSF secretion.\",Confirms apical NKCC1 role in
secretion.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S07,ReviewDirectional,ChoroidPlexus_Transport,Basolateral
HCO3- transport,Mechanism,\"Basolateral Na+ uptake mediated by Na+-HCO3-
cotransporter (NCBE/Slc4a10) and
NHE1.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Basolateral
Na+ uptake via NCBE and NHE1.\",Defines basolateral ion loading
mechanism.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S08,ReviewDirectional,ChoroidPlexus_Transport,Basolateral
HCO3- transport,Mechanism,\"Basolateral Cl- uptake mediated by Cl-/HCO3-
exchanger
(AE2/Slc4a2).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Basolateral
Cl- uptake via AE2.\",Defines basolateral ion loading
mechanism.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S09,ReviewDirectional,AQP1,AQP1
localization,AnatomicalPathway,\"AQP1 is highly expressed at the apical
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"AQP1 is
apical.\",Defines AQP1
polarity.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Mouse,Healthy,NR,S10,ReviewNumericSummary,AQP1,AQP1
contribution to CSF secretion,FractionContribution,\"AQP1 knockout mice
show a \~20% reduction in CSF
secretion.\",Continuous,WT,NR,NR,NR,AQP1_KO,NR,NR,NR,PercentChange,-20,NR,NR,NR,NR,\"AQP1
deletion has modest (20%) effect on CSF secretion.\",Quantifies AQP1
contribution.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S11,ReviewDirectional,CSF_Production,CSF
secretion vs osmotic gradient,Mechanism,\"CSF secretion occurs even
against an opposing osmotic
gradient.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF
secretion is non-osmotic.\",Refutes simple osmotic
models.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Damkier_2013_PhysiolRev,Damkier,2013,Physiol
Rev,PhysiologyReview,NotSpecified,Rat,Healthy,NR,S12,ReviewNumericSummary,CSF_Production,CSF
production rate (Rat),Rate,\"Rat CSF production rate \~10
ul/min.\",Continuous,Rat,10,NR,NR,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Rat CSF
production rate \~10 ul/min.\",Sets baseline CSF production rate for
rat.,damkier-et-al-2013-cerebrospinal-fluid-secretion-by-the-choroid-plexus.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,CSF_Production,CSF
production origin,Mechanism,\"Majority of CSF is secreted by the choroid
plexus
epithelium.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CP is
the major source of CSF.\",Defines CP as main production
site.,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,ChoroidPlexus_Transport,Secretion
mechanism,Mechanism,\"CSF secretion is driven by solute transport (ions)
creating an osmotic gradient for
water.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Secretion
is driven by solute transport.\",Defines general mechanism
(pre-cotransport era).,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,NaK_ATPase,NaK-ATPase
localization,AnatomicalPathway,\"Na+/K+-ATPase is located on the apical
(CSF-facing)
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
apical (CSF-facing).\",Defines polarity of primary secretion
driver.,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,NKCC1,NKCC1
localization,AnatomicalPathway,\"NKCC1 (Na-K-2Cl cotransporter) is
located on the apical
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKCC1 is
apical.\",Defines NKCC1 polarity.,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S05,ReviewDirectional,ChoroidPlexus_Transport,Basolateral
HCO3- transport,Mechanism,\"Basolateral mechanisms include AE2
(Cl-/HCO3- exchange) and NBC (Na+-HCO3-
cotransport).\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Basolateral
ion loading via AE2 and NBC.\",Defines basolateral ion loading
mechanism.,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide (CA inhibitor) reduces CSF secretion
by inhibiting carbonic
anhydrase.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ
inhibits CA to reduce CSF secretion.\",Defines ACZ
mechanism.,PIIS0306452204005640.pdf

Brown_2004_Neuroscience,Brown,2004,Neuroscience,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S07,ReviewDirectional,AQP1,AQP1
localization,AnatomicalPathway,\"AQP1 is expressed on the apical
membrane.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"AQP1 is
apical.\",Defines AQP1 polarity.,PIIS0306452204005640.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,NaK_ATPase,NaK-ATPase
localization,AnatomicalPathway,\"Na+/K+-ATPase (NKA) is almost
exclusively expressed on the apical membrane of CP epithelial
cells.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
apical (CSF-facing).\",Defines polarity of primary secretion
driver.,s12987-019-0129-6.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,NaK_ATPase,NaK-ATPase
role,Mechanism,\"NKA is the principal transporter responsible for CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
the principal driver of secretion.\",Confirms NKA as primary
driver.,s12987-019-0129-6.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,NaK_ATPase,NaK-ATPase
inhibition (Ouabain),Mechanism,\"Ouabain (NKA inhibitor) reduces CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA
inhibition reduces CSF secretion.\",Confirms NKA
mechanism.,s12987-019-0129-6.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,NaK_ATPase,NKA
and IIH,Mechanism,\"A possible role for NKA in IIH: increased NKA
activity could lead to increased CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"Hypothesis:
Increased NKA activity in IIH.\",Links NKA mechanism to IIH
pathophysiology.,s12987-019-0129-6.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Rat,Healthy,NR,S05,ReviewNumericSummary,NaK_ATPase,NKA
isoforms (Rat),ExpressionLevel,\"NKA isoform expression in rat CP: α1
(96%), α2 (3.5%), α3
(0.5%).\",Conceptual,α1,96,NR,NR,α2,3.5,NR,NR,PercentContribution,NA,NA,NA,NR,NR,\"α1
isoform is dominant in rat CP.\",Specifies dominant NKA
isoform.,s12987-019-0129-6.pdf

Brown_2019_FluidsBarriersCNS,Brown,2019,Fluids Barriers
CNS,NarrativeReview,NotSpecified,Multiple,Healthy,NR,S06,ReviewDirectional,Acetazolamide,ACZ
and NKA activity,Mechanism,\"Acetazolamide does \*not\* directly inhibit
NKA activity.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ
does not inhibit NKA.\",Distinguishes ACZ mechanism from
NKA.,s12987-019-0129-6.pdf

McComb_1985_JPediatr,McComb,1985,J
Pediatr,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,NaK_ATPase,NaK-ATPase
role,Mechanism,\"Na+/K+-ATPase is the rate-limiting enzyme for CSF
production.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA is
rate-limiting for CSF production.\",Confirms NKA as primary
driver.,PIIS0022347685806090.pdf

McComb_1985_JPediatr,McComb,1985,J
Pediatr,ConceptualReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide (CA inhibitor) reduces CSF
production by limiting H+ and HCO3-
availability.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"ACZ
limits substrates (H+, HCO3-).\",Defines ACZ
mechanism.,PIIS0022347685806090.pdf

Segal_1977_ExpEyeRes,Segal,1977,Exp Eye
Res,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S01,ReviewDirectional,CSF_Production,CSF
secretion vs ultrafiltrate,Mechanism,\"CSF is a secretion, not an
ultrafiltrate of
plasma.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"CSF is an
active secretion.\",Establishes active transport
principle.,PIIS0022347668803191.pdf

Segal_1977_ExpEyeRes,Segal,1977,Exp Eye
Res,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S02,ReviewDirectional,CSF_Production,Choroid
plexus vs extrachoroidal,FractionContribution,\"Choroid plexus is the
main site of CSF formation
(50-80%).\",Conceptual,CP,NR,NR,NR,Extrachoroidal,NR,NR,NR,PercentContribution,50-80,NR,NR,NR,NR,\"CP
accounts for 50-80% of CSF production.\",Quantifies CP
contribution.,PIIS0022347668803191.pdf

Segal_1977_ExpEyeRes,Segal,1977,Exp Eye
Res,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S03,ReviewDirectional,NaK_ATPase,NaK-ATPase
inhibition (Ouabain),Mechanism,\"Ouabain (Na+/K+-ATPase inhibitor)
markedly reduces CSF
secretion.\",Conceptual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NR,\"NKA
inhibition reduces CSF secretion.\",Confirms NKA as primary
driver.,PIIS0022347668803191.pdf

Segal_1977_ExpEyeRes,Segal,1977,Exp Eye
Res,PhysiologyReview,NotSpecified,Multiple,Healthy,NR,S04,ReviewDirectional,Acetazolamide,Acetazolamide
mechanism,Mechanism,\"Acetazolamide reduces CSF formation by \~50% by
inhibiting carbonic
anhydrase.\",Conceptual,Control,NR,NR,NR,Acetazolamide,NR,NR,NR,PercentChange,-50,NR,NR,NR,NR,\"ACZ
inhibits \~50% of CSF formation via CA inhibition.\",Quantifies ACZ
effect.,PIIS0022347668803191.pdf
